Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Doctors And Hospitals Look For Ways To Cut Costs, Improve Quality
The "patient-centered" practices movement is growing in popularity, the New York Times reports. Primary care physicians in the practices "spend more time with patients, emphasize prevention and education" to keep patients healthy and "can handle many medical problems without referrals to specialists." Often, "this kind of care can reduce a patient"s medical bills." Dr. Jose Batlle, a doctor in the Bronx, for example, gives patients his cell phone number and helps his patients cut down on the number of prescription drugs that have him prescribed to them by multiple specialists. "I prefer to keep them healthy than treat them when they are sick," Batlle says.

North Carolina State University And The University Of Strasbourg Agree To Collaborate On A Training Program
Strasbourg University and North Carolina State University, both leading academic institutions in the field of bioproduction, have entered into an agreement to collaborate on a unique set of training capabilities for industry. The Alsace Biovalley cluster has played and will continue to play a key role in the program by bringing together industry players in support of the project, ensuring that training programs meet industry needs, structuring the financial engineering required and securing funding for the infrastructures.
News of the day
Oncologic Drugs Advisory Committee Meeting Set By FDA
Medical Industry E-Mail News Service™ -- July 07 2009 -- The US Food & Drug Administration (FDA) has announced that its Oncologic Drugs Advisory Committee will meet on July 15 2009, in Gaithersburg MD, to discuss (1) new drug application (NDA) 022-447, proposed trade name Yondelis (trabectedin) powder, for concentrate for solution for intravenous infusion, Centocor Ortho Biotech Products, L.P., proposed indication in combination with Doxcil (doxorubicin HCl liposome injection), for treating patients with relapsed ovarian cancer; and (2) supplemental new drug application (sNDA) 050-718/S-039, Doxil (doxorubicin HCl liposome injection), for intravenous infusion, Centocor Ortho Biotech Products, L.P., proposed indication in combination with docetaxel for treating patients with locally advanced or metasatic breast cancer who have received prior anthracycline treatment. There is no charge to attend.
Oncology

Presentation Of The National Consortium For Translational Cancer Research

No progress without research - this is particularly true for cancer medicine. The chances of cure for those affected can only be further increased if research results are swiftly transferred from the laboratory into clinical practice. Framework conditions for this research transfer, also called translational research, will now be optimized in Germany. Last Tuesday, German Research Minister Annette Schavan, Friedrich Carl Janssen, Chairman of German Cancer Aid (Deutsche Krebshilfe), and Professor Dr. Otmar D. Wiestler, Scientific Director of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) presented the "National Consortium for Translational Cancer Research" in Berlin. "Each year, more than 436,000 people in Germany are newly diagnosed with cancer, 210,000 patients die of cancer every year. Therefore, it is important to translate the latest findings of cancer research even more rapidly into patient care. To this end, we have founded the National Consortium for Translational Cancer Research," Schavan said. "We intend to further strengthen Germany"s leading role in cancer research." The consortium is established on the initiative of the Federal Ministry of Education and Research (Bundesministerium fÃør Bildung und Forschung, BMBF), German Cancer Aid (Deutsche Krebshilfe) and the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ). The financial res needed for the whole consortium over a period of ten years amount to 400 million euros. "It has always been an endeavor of German Cancer Aid as a private organization to implement large projects jointly with public entities in order to create synergies. Apart from the fact that it makes sense for important private initiatives to collaborate with political institutions, ambitious projects can only be shouldered together. The joint project presented today is an excellent, future-oriented example of such a partnership," Janssen emphasized. Key tasks of the national consortium include the creation and use of effective translational research units at partnering sites within a network throughout Germany. The DKFZ in Heidelberg as the core research center will collaborate with selected partners at university hospitals at up to six sites. "In this collaboration, DKFZ will be supported by excellent partners that will provide access to patients, samples and an effective clinical environment. In return, the sites will be given access to DKFZ"s research programs," said Schavan. The sites will be selected by a committee of international experts by early 2010. "Cancer research in Germany has gained an enormous amount of new findings in recent years. We understand more and more of the fundamental causes and development processes of cancer - what matters now is that we transport this knowledge as swiftly and directly as possible into the clinical care of cancer patients," Professor Otmar D. Wiestler explained. "At the German Cancer Research Center, we have been able to gather a unique body of expertise for tight networking among basic research and clinical practice thanks to the foundation of the National Center for Tumor Diseases. Thus, we have created the best prerequisites for coordinating and advancing translational, i.e. application-oriented, cancer research in Germany under the leadership of our Center." At the same time, research minister Schavan announced that the Federal Ministry of Education and Research and German Cancer Aid will jointly support the participation of a German research consortium in the International Cancer Genome Consortium (ICGC). Both partners will jointly provide funds of approximately 15 million euros over a period of five years. This is intended as a contribution to the fight against tumor diseases with particularly high mortality. The ICGC aims to analyze the genetic changes in tumors of all human organ systems in order to facilitate and customize new and better applications in the areas of diagnosis, treatment and prevention of the respective cancer types. The results will rapidly be made available to the research community as a basis for further research work. The project is planned to be launched in fall 2009. The ICGC is a large-scale biomedical project in which leading cancer researchers have joined forces. Dr. Stefanie Seltmann Helmholtz Association of German Research Centres


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009